Imbruvica & Vimizim registered for insurance benefits under special case system
A series of rare disease products that are applied by the special case system of economic evaluation will be registered for the health insurance benefit.
They are the Janssen’s mantle cell lymphoma treatment Imbruvica(ibrutinib) and Sam-Oh Pharm’s morquio A syndrome treatment Vimizim(elosulfase...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
